File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Chemotherapy for advanced non-small-cell lung cancer: Role of paclitaxel and gemcitabine

TitleChemotherapy for advanced non-small-cell lung cancer: Role of paclitaxel and gemcitabine
Authors
KeywordsAntineoplastic agents/therapeutic user
Carcinoma, non-small-cell lung/drug therapy
Cisplatin
Deoxycytidine/analogs and derivatives
Paclitaxel
Survival rate
Issue Date1999
PublisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.html
Citation
Hong Kong Medical Journal, 1999, v. 5 n. 2, p. 180-186 How to Cite?
AbstractObjective. To review the role of chemotherapy in advanced non-small-cell lung cancer, focusing on cisplatin-based regimens and two new drugs: paclitaxel and gemcitabine. Data sources. Medline search of the relevant English literature. Study selection. Open and randomised comparative (phases II and III) studies, and meta-analyses of cytotoxic drugs/regimens used to treat advanced non-small-cell lung cancer. Data extraction. The following factors were studied and compared: symptomatic response rates; tumour response rates; median survival time and 1-year survival rates; and side effects of cisplatin-, paclitaxel-, and gemcitabine-based regimens. Data synthesis. Using cisplatin-based chemotherapy achieves significant relief of disease-related symptoms of advanced non-small-cell lung cancer and a slight improvement in the median survival time (by approximately 1.5 months). New cytotoxic drugs that are effective and have good safety profiles include paclitaxel and gemcitabine. When used as single agents, these two drugs give response rates of approximately 25%. When used with cisplatin/carboplatin, response rates increase to 45% to 62% and 1-year survival rates increase to 40% to 60%. Conclusion. Paclitaxel, gemcitabine, and other drugs such as decetaxel and vinorelbine are promising new chemotherapeutic agents in the treatment of advanced non-small-cell lung cancer. These drugs can palliate disease symptoms and improve the median survival time. The optimal dose and treatment schedules, however, are yet to be defined.
Persistent Identifierhttp://hdl.handle.net/10722/45097
ISSN
2015 Impact Factor: 0.887
2015 SCImago Journal Rankings: 0.279

 

DC FieldValueLanguage
dc.contributor.authorLam, WKen_HK
dc.contributor.authorTsang, KWTen_HK
dc.contributor.authorIp, MSMen_HK
dc.date.accessioned2007-10-30T06:17:22Z-
dc.date.available2007-10-30T06:17:22Z-
dc.date.issued1999en_HK
dc.identifier.citationHong Kong Medical Journal, 1999, v. 5 n. 2, p. 180-186en_HK
dc.identifier.issn1024-2708en_HK
dc.identifier.urihttp://hdl.handle.net/10722/45097-
dc.description.abstractObjective. To review the role of chemotherapy in advanced non-small-cell lung cancer, focusing on cisplatin-based regimens and two new drugs: paclitaxel and gemcitabine. Data sources. Medline search of the relevant English literature. Study selection. Open and randomised comparative (phases II and III) studies, and meta-analyses of cytotoxic drugs/regimens used to treat advanced non-small-cell lung cancer. Data extraction. The following factors were studied and compared: symptomatic response rates; tumour response rates; median survival time and 1-year survival rates; and side effects of cisplatin-, paclitaxel-, and gemcitabine-based regimens. Data synthesis. Using cisplatin-based chemotherapy achieves significant relief of disease-related symptoms of advanced non-small-cell lung cancer and a slight improvement in the median survival time (by approximately 1.5 months). New cytotoxic drugs that are effective and have good safety profiles include paclitaxel and gemcitabine. When used as single agents, these two drugs give response rates of approximately 25%. When used with cisplatin/carboplatin, response rates increase to 45% to 62% and 1-year survival rates increase to 40% to 60%. Conclusion. Paclitaxel, gemcitabine, and other drugs such as decetaxel and vinorelbine are promising new chemotherapeutic agents in the treatment of advanced non-small-cell lung cancer. These drugs can palliate disease symptoms and improve the median survival time. The optimal dose and treatment schedules, however, are yet to be defined.en_HK
dc.format.extent43100 bytes-
dc.format.extent21099 bytes-
dc.format.extent18665 bytes-
dc.format.extent21721 bytes-
dc.format.mimetypeapplication/pdf-
dc.format.mimetypetext/plain-
dc.format.mimetypetext/plain-
dc.format.mimetypetext/plain-
dc.languageengen_HK
dc.publisherHong Kong Medical Association. The Journal's web site is located at http://www.hkmj.org/resources/supp.htmlen_HK
dc.relation.ispartofHong Kong Medical Journalen_HK
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License-
dc.subjectAntineoplastic agents/therapeutic useren_HK
dc.subjectCarcinoma, non-small-cell lung/drug therapyen_HK
dc.subjectCisplatinen_HK
dc.subjectDeoxycytidine/analogs and derivativesen_HK
dc.subjectPaclitaxelen_HK
dc.subjectSurvival rateen_HK
dc.titleChemotherapy for advanced non-small-cell lung cancer: Role of paclitaxel and gemcitabineen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1024-2708&volume=5&issue=2&spage=180&epage=186&date=1999&atitle=Chemotherapy+for+advanced+non-small-cell+lung+cancer:+role+of+paclitaxel+and+gemcitabineen_HK
dc.identifier.emailIp, MSM:msmip@hku.hken_HK
dc.identifier.authorityIp, MSM=rp00347en_HK
dc.description.naturepublished_or_final_versionen_HK
dc.identifier.pmid11821589en_HK
dc.identifier.scopuseid_2-s2.0-0032823249en_HK
dc.identifier.hkuros51475-
dc.identifier.volume5en_HK
dc.identifier.issue2en_HK
dc.identifier.spage180en_HK
dc.identifier.epage186en_HK
dc.publisher.placeHong Kongen_HK
dc.identifier.scopusauthoridLam, WK=7203021937en_HK
dc.identifier.scopusauthoridTsang, KWT=7201555024en_HK
dc.identifier.scopusauthoridIp, MSM=7102423259en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats